Cue Biopharma enters $20M SVB loan facility with tranche A of $10M available immediately

Cue Biopharma, Inc.

Tranche A of $10M funded at closing; two additional tranches up to $5M each contingent on CUE-101 data and equity proceeds.
Interest rate: prime plus 2.25% (floor 5.5%); repayment begins June 2023 or Dec 2023 if tranche B advanced; maturity Dec 2025.
Prepayment premium: 3% within 1yr, 2% 1-2yr, 1% after 2yr; final payment fee 5% of original principal.
Secured by substantially all assets except IP (negative pledge); requires cash at SVB equal to lesser of all cash or 110% of obligations.
Standard events of default; default triggers 3% rate increase and acceleration of all obligations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.